Fineheart key facts
as of Oct 2026- Developer of implantable cardiac devices designed to treat cardiovascular diseases.
- Fineheart is valued at approximately $48.8M as of Oct 2026 (last reported valuation).
- It has raised $75.6M; the latest was Grant ($56.3M) in Jan 2026.
- Notable investors include European Innovation Council, MedTech Innovator, UI Investissement, Verve Ventures, European Regional Development Fund (Brandenburg) — 21 tracked in total.
- Status: Privately Held (backing).
Fineheart's last reported valuation, Dec 2021. Nothing priced has surfaced since.
- ·The complete investor list: 21 names
- ·Watch Fineheart: the Monday email on marks, rounds and moves
Fineheart funding rounds
No funding rounds for Fineheart are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Fineheart
21+Fineheart valuation
Fineheart's last reported valuation was $48.8 million in Dec 2021. No priced round, secondary trade or fund mark has surfaced since.
Fineheart investors
21 investors are on record for Fineheart, including European Innovation Council, MedTech Innovator, UI Investissement and Verve Ventures.
About Fineheart
Developer of implantable cardiac devices designed to treat cardiovascular diseases. The company's device is a novel, wirelessly powered, fully implantable mechanical circulatory support device that can optimize cardiac output while preserving the heart's innate contractility, enabling patients to restore normal cardiac output and allow heart failure patients to return to a normal quality of life.
- Sector
- Healthcare
- HQ
- Pessac, France
- Founded
- 2010
- Employees
- 88
- Website
- fineheart.fr/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.